imidacloprid / Moxidectin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2015
0120042015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Heartworm disease in dogs can be severe and life threatening. Resistance to available heartworm preventives was considered among… (More)
  • table 1
  • table 1
  • table 2
  • table 2
  • table 3
Is this relevant?
2016
2016
The efficacy of oral treatment with a chewable tablet containing afoxolaner 2.27% w/w (NexGard(®), Merial) administered orally… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2015
2015
This study aimed to evaluate the efficacy of imidacloprid 10 %/moxidectin 2.5 % (w/v) spot-on (Advocate®/Advantage® Multi, Bayer… (More)
  • table 1
  • figure 1
  • figure 4
  • figure 2
  • figure 5
Is this relevant?
2011
2011
Canine angiostrongylosis is an emerging cardiopulmonary disease in Europe which can be fatal if left untreated. We developed a… (More)
  • table 1
Is this relevant?
2005
2005
Efficacy and safety of treatment with imidacloprid 10%+moxidectin 2.5% spot-on (Advocate®, Advantage multi®; Bayer AG, Leverkusen… (More)
Is this relevant?
2005
2005
Efficacy and safety of the test product imidacloprid 10%+moxidectin 2.5% spot on (Advocate®, Advantage multi®) in the treatment… (More)
  • figure 1
Is this relevant?
2004
2004
A study was conducted to determine the safety of the dermal application of 10% imidacloprid/2.5% moxidectin topical solution in… (More)
Is this relevant?